HCM
CHRS icon

Highbridge Capital Management’s Coherus Oncology CHRS Stock Holding History

Highbridge Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,700
Closed -$269K – 1506
2015
Q4 		$269K Buy
+11,700
New +$301K ﹤0.01% 1232

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highbridge Capital Management's CHRS Position: Q2 2018 in Review

Highbridge Capital Management sold out of Coherus Oncology (CHRS) in Q2 2018, closing a stake of 375,000 shares — an estimated $4.14M sold.

Highbridge Capital Management first reported a position in CHRS in Q1 2016 and held it in 5 quarters. The position peaked at $4.14M in Q1 2018. 115 funds tracked by Wall St. Rank hold CHRS as of Q2 2018.

  • Highbridge Capital Management reported no remaining Coherus Oncology position as of Q2 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 375,000 Coherus Oncology shares in Q2 2018, an estimated $4.14M.
  • Highbridge Capital Management first reported a position in Coherus Oncology in Q1 2016 and held it in 5 quarters.
  • Highbridge Capital Management's Coherus Oncology position peaked at $4.14M in Q1 2018.
  • 115 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.